Is Aprea Therapeutics, Inc. (APRE) a Buy, Sell, or Hold?
Aprea Therapeutics, Inc.
NASDAQ:APRE
$0.7284 USD
$0.01 (0.89%)
- Volume
- 145.65K
- Average Volume
- 168.41K
- Market Capitalization
- $4.73M
- P/E Ratio
- -0.42
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $2.22
- Year Low
- $0.55
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $8.92
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Oren Gilad |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | APRE |
| CUSIP | 03836J201 |
| CIK | 0001781983 |
| Web | https://www.aprea.com |
| Phone | 617-463-9385 |
| Currency | USD |
| Employees | 8 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 8.92 |
| Quick Ratio | 8.92 |
| Cash Ratio | 8.77 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 40.05 |
| Cash Flow | -1.59 |
| Price / Cash Flow | -0.39 |
| Price / Book | 0.13 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 8 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.93 |
| Trailing P/E Ratio | -0.42 |
| PEG Ratio | -0.01 |
| P/E Growth | -0.01 |
| Net Income | $-12.6M |
| Net Margin | -10121.69% |
| Pretax Margin | -10121.69% |
| Return on Equity | -59.54% |
| Return on Assets | -24.85% |
Financials Score
| AltmanZ Score | -9.04 |
| Piotroski Score | 2.00 |
| Working Capital | 41.95M |
| Total Assets | 48.11M |
| Ebit | -11.95M |
| Market Cap | 4.73M |
| Total Liabilities | 5.3M |
Poll Results
About Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts. ...
2026-06-01 08:00:00
Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types Manageable tolerability confirmed across cohorts Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027 DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” on May 30 at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, taking place in Chicago, Illinois.
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know
2026-05-21 13:02:09
Aprea Therapeutics (APRE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-13 06:30:00
DOYLESTOWN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
2026-05-07 08:14:07
Pre-Market Stock Futures: Futures are trading modestly higher after a blowout midweek rally spurred by reports that a peace agreement with Iran could be forthcoming soon and by incredible technology earnings and forecasts that destroyed Wall Street estimates. All of the major indices were once again printing new highs as investors cheered the potential for... Here Are Thursday's Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
2026-04-21 10:15:00
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to take place May 29 - June 2, 2026, in Chicago, IL.
Frequently Asked Questions
-
What is the current Aprea Therapeutics, Inc. (APRE) stock price?
-
Aprea Therapeutics, Inc.(NASDAQ:APRE) stock price is $0.7284 in the last trading session. During the trading session, APRE stock reached the peak price of $2.22 while $0.548 was the lowest point it dropped to. The percentage change in APRE stock occurred in the recent session was 0.89% while the dollar amount for the price change in APRE stock was $0.01.
-
APRE's industry and sector of operation?
-
The NASDAQ listed APRE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of APRE?
-
Oren Gilad | Co-Founder, Chief Executive Officer, President and Director
Lars Abrahmsen | Senior Vice President & Chief Scientific Officer
Michel Afargan | Head of Pharmacology Development
Eugene Kennedy | Chief Medical Advisor
John Hamill | Senior Vice President, Chief Financial Officer, Principal Accounting Officer & Secretary -
How many employees does APRE have?
-
Number of APRE employees currently stands at 8. APRE operates from 535 Boylston St., Boston, PA 02116, US.
-
Link for APRE official website?
-
Official Website of APRE is: https://www.aprea.com
-
How do I contact APRE?
-
APRE could be contacted at phone #617-463-9385 and can also be accessed through its website. APRE operates from 535 Boylston St., Boston, PA 02116, US.
-
How many shares of APRE are traded daily?
-
The average number of APRE shares traded daily for last 3 months was 168.41K.
-
What is the market cap of APRE currently?
-
The market value of APRE currently stands at $4.73M with its latest stock price at $0.7284